Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 15.375p 14.75p 16.00p 15.375p 15.375p 15.375p 54,341 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 11.39

Evgen Pharma Share Discussion Threads

Showing 526 to 548 of 550 messages
Chat Pages: 22  21  20  19  18  17  16  15  14  13  12  11  Older
DateSubjectAuthorDiscuss
13/12/2017
10:16
Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes
rathean
13/12/2017
08:50
Floated at 37p? And only had good news since
tilly99
13/12/2017
08:35
Dave Doubt it!!All time low and great collaborations !
tilly99
13/12/2017
07:33
Great news about Kings and Stroke. Here is some published information on their work with sulforaphane and stroke hTTp://onlinelibrary.wiley.com/doi/10.1113/jphysiol.2013.257964/full
pdt
12/12/2017
20:51
Could also be 12p!
dave444
11/12/2017
11:06
Great piece from EvgDave you could be right!! 100p wow
tilly99
11/12/2017
11:01
Just goes to show there are no slam dunks in the biotech business. The researchers in this COPD trial sound utterly bewildered by the result, but all credit to them for publishing... http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163716
supernumerary
11/12/2017
09:36
RNS 3rd party research RNS stating Evgen phase two trials now fully funded with results expected later in 2018.
rathean
10/12/2017
13:00
1pd?Really? Wow
tilly99
09/12/2017
13:51
I would not be surprised if it hit 12p but a £1/share price would not surprise me by February
dave444
09/12/2017
13:25
Dave444Price tgt?
tilly99
09/12/2017
10:37
I see they now have two live recruiting sites in Belgium, one in Spain and four in the UK. With others listed in France, Spain and the UK which are not yet recruiting. Looks like they will hit their date of end of 2018 for metastatic breast cancer. However, I would expect them to tie up a licence deal long before then. Possibly even before the H1 2018 interim read out. There should be good newsflow in 2018 with other activities and third party investigations. I did see MS was not mentioned but Stroke (other than subarachnoid) and Brain cancer seem to be new?
pdt
08/12/2017
16:58
Clearly a placing would hav that impact smart ass!!
dave444
08/12/2017
16:49
dave444 5 Dec '17 - 08:12 - 89 of 95 0 0 Well just had a small top up as 15p seems to be as low as it goes dave444 6 Dec '17 - 08:35 - 92 of 95 0 0 Should be a good run up to Xmas >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Obviously not!
papillon
08/12/2017
12:47
Rathean - agreed. That was the section I was going to cut and paste. Excellent news on nearly 12 month disease free progression for one person and others over 24 week disease free progression. This is a hugely valuable market. $5 billion per annum I believe was mentioned in the Hardman report. And an amazing scientific breakthrough potentially turning metastatic breast cancer from a death sentence to a manageable condition. As Stephen Franklin was quoted in The Times article recently. This will literally save/extend hundreds of thousands of lives. And good news on resolving the funding which was hanging over the company. Only disappointing news I saw was that the stroke trial has probably been delayed a few months. I think the phrase is now "around year end" to finish.
pdt
08/12/2017
11:08
From the results:We are particularly pleased with the progress of the STEM trial and the requirement to open the compassionate use programme for patients that have had their tumour growth arrested for the full duration of the 24-week trial and wish to receive SFX-01 post-trial on ethical grounds. We now have one STEM patient that has been on SFX-01 for nearly a year with demonstrable clinical benefit and others that have entered the compassionate use programme.Successful placing and strong progress with SFX-01. One to top up and tuck under your pillow.
rathean
07/12/2017
13:25
Reached my buy-in price, pleased it fell back and maybe more to go with general sentiment today but firm believer in the science and progress made so far.
rathean
06/12/2017
08:35
Should be a good run up to Xmas
dave444
06/12/2017
08:11
I must be a prophet or something- ok more like something
dave444
06/12/2017
08:05
More upward momentum
dave444
05/12/2017
08:12
Well just had a small top up as 15p seems to be as low as it goes
dave444
28/11/2017
11:59
In for a nibble here at 16p. Strikes me as a buy and tuck away kind of share.
qazwsxedc69
24/11/2017
10:17
I also agree Timbo, looks like the price is sinking back to where it started. Seperately I see there has been a positive follow up on an earlier autism study. And Evgen have mentioned they may work with St Thomas's in 2018 on an Autism study. "Sulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study" hTTp://journals.sagepub.com/doi/10.1177/2164957X17735826 From the original study: "Of the 26 participants who were taking SF throughout the study, 17 (65%) improved significantly, most of whom returned to baseline levels 4 weeks after terminating the intervention. None of those on placebo had changed significantly."
pdt
Chat Pages: 22  21  20  19  18  17  16  15  14  13  12  11  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171214 20:58:27